BTQNF yields 3.92% · MRK yields 2.76%● Live data
📍 MRK pulled ahead of the other in Year 1
Combined, BTQNF + MRK cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BTQNF + MRK for your $10,000?
BQE Water Inc., a water treatment company, provides wastewater management and treatment services to the mining and metallurgical industry in Canada, the United States, Latin America, China, and internationally. It offers water treatment solutions for mine drainage, run-off, waste rock seepage, tailings water, groundwater, and lime plant influent and/or effluent streams for treating metals, sulphate, selenium, nitrate, ammonia, and cyanide in the mining sector; smelting and refining services for treating metals and sulphate; and hydrometallurgy services for the treatment of metals, cyanide, and acids. The company's metal recovery and removal technologies include BioSulphide and ChemSulphide technologies, which use biological or chemical sources of sulphide to remove dissolved metals from mining wastewater; and Met-IX technology that treats wastewater. It also offers sulphate technologies, such as Sulf-IX and Sulf-IXC, which removes sulphate and hardness from process water, as well as onsite field testing to remove sulphate from wastewater; selenium removal technology, including Selen-IX that removes selenium from mining wastewater, as well as on-site field testing to demonstrate selenium removal from mine impacted waters; and cyanide treatment technologies, such as SART to remove the metallurgical interference of cyanide-soluble metals and to recover and recycle cyanide in gold processing. The company was formerly known as BioteQ Environmental Technologies Inc. and changed its name to BQE Water Inc. in March 2017. BQE Water Inc. was founded in 1997 and is headquartered in Vancouver, Canada.
Full BTQNF Calculator →Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Full MRK Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.